Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM0MI81)

Drug Name
Bevacizumab + Erlotinib Drug Info
Indication
Disease Entry ICD 11 Status REF
Metastatic colorectal cancer 2B91 Phase 3 [1] , [2]
Non-small-cell lung cancer 2C25.Y Phase 3 [1] , [2]
Hepatocellular carcinoma 2C12.02 Phase 2 [3] , [4] , [5] , [6] , [7] , [8]
Hypopharyngeal squamous cell carcinoma 2B6D.0 Phase 1/2 [9]
Cross-matching ID
TTD Drug ID
DM0MI81

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Epidermal growth factor receptor (EGFR) TTGKNB4 EGFR_HUMAN Inhibitor [10]
Vascular endothelial growth factor A (VEGFA) TTOHSBA VEGFA_HUMAN Inhibitor [10]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Vascular endothelial growth factor A (VEGFA) DTT VEGFA 8.544 6.927 7.253 7.839
Epidermal growth factor receptor (EGFR) DTT EGFR 6.045 4.991 5.317 5.252
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Metastatic colorectal cancer
ICD Disease Classification 2B91
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Vascular endothelial growth factor A (VEGFA) DTT VEGFA 3.61E-01 0.15 0.47
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT00130728) A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer
2 ClinicalTrials.gov (NCT00598156) Chemotherapy and Avastin Followed by Maintenance Treatment With Avastin +/- Tarceva
3 ClinicalTrials.gov (NCT01130519) A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer. U.S. National Institutes of Health.
4 ClinicalTrials.gov (NCT00287222) Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma
5 ClinicalTrials.gov (NCT02655536) Bevacizumab and Erlotinib in Lung Cancer With Brain Metastases, a Phase II Trial
6 Combined inhibition of vascular endothelial growth factor and epidermal growth factor signaling in non-small-cell lung cancer therapy. Clin Lung Cancer. 2009 Mar;10 Suppl 1:S17-23.
7 Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet. 2011 May 28;377(9780):1846-54.
8 ClinicalTrials.gov (NCT00365391) Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer
9 ClinicalTrials.gov (NCT00055913) Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
10 Clinical pipeline report, company report or official report of Roche (2009).